Company
Headquarters: Secaucus, NJ, United States
Founded: New York City, United States 1967
Employees: 40,000
CEO: Mr. Stephen H. Rusckowski
$15.60 Billion
USD as of July 1, 2024
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $204.45 B |
Danaher | $177.21 B |
Siemens Healthineers AG | $63.84 B |
DexCom, Inc. | $45.21 B |
Lonza Group Ltd | $39.85 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Quest Diagnostics Incorporated has the following listings and related stock indices.
Stock: NYSE: DGX wb_incandescent
Stock: XETR: QDI wb_incandescent
Medical testing Molecular diagnostics Clinical chemistry
Founder(s): Paul Brown
Steve Rusckowski (Chairman, President, & CEO)
Revenue: US$7.73 billion (2019)
Operating income: US$1.31 billion (2019)
Net income: US$838 million (2019)
Total assets: US$12.843 billion (2019)
Total equity: US$4.921 billion (2019)